Research Peptides
A high-purity research peptide studied in growth-hormone research. Available in 5mg and 10mg, with every batch independently tested and dispatched from the UK.
A high-purity research peptide studied in growth-hormone research. Available in 5mg and 10mg, with every batch independently tested and dispatched from the UK.
Ipamorelin peptide UK is Crown Peptides' selective synthetic growth-hormone secretagogue peptide, available in 5mg and 10mg strengths for laboratory research.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
Ipamorelin is a synthetic pentapeptide studied as a relatively selective agonist of the growth-hormone secretagogue receptor. It belongs to the ghrelin-mimetic family of compounds but is structurally distinct from endogenous ghrelin.
Ipamorelin research focuses on GHSR receptor pharmacology, pituitary growth-hormone release and endocrine selectivity, first characterised in the literature as the original selective secretagogue in its class (Learn more). It is frequently compared with earlier growth-hormone-releasing peptides such as [GHRP-6] to examine differences in receptor selectivity and secondary endocrine signalling. This makes it useful in mechanistic studies of the ghrelin-growth-hormone axis, often studied alongside [CJC-1295 with DAC].
Compound-level reference data. Batch-specific results appear on the Certificate of Analysis.
Work out concentration with the peptide calculatorCrown Peptides Ipamorelin is supplied for controlled laboratory research with batch-specific analytical documentation. High-Performance Liquid Chromatography (HPLC) can assess chromatographic purity, while Mass Spectrometry provides molecular information used to support identity verification.
The batch-specific Certificate of Analysis is the definitive source for the exact purity result, identity data and analytical specification of the material supplied.
Researchers working with Ipamorelin may also be interested in [GHRP-6], [CJC-1295 with DAC], [CJC-1295 + Ipamorelin], [Sermorelin] and [Tesamorelin] — other growth-hormone-releasing peptides studied in the same endocrine research pathway.
Ipamorelin is a synthetic pentapeptide studied as a selective growth-hormone secretagogue receptor agonist, supplied by Crown Peptides in 5mg and 10mg strengths.
Research focuses on the GHSR or ghrelin receptor.
Studies examine receptor pharmacology, pituitary growth-hormone signalling and endocrine selectivity.
Ipamorelin acts through the ghrelin/GHSR pathway rather than the GHRH receptor used by peptides such as [CJC-1295 with DAC].
Applicable peptide batches are assessed with HPLC and Mass Spectrometry, with exact analytical results on the batch-specific Certificate of Analysis.
Every batch is published openly — identity, purity and batch number, with no account needed.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
Each batch undergoes internal analytical verification using chromatographic and spectrometric methods prior to lyophilisation.
• HPLC Analysis
• Mass Spectrometry Confirmation
• Batch Traceability
By purchasing this product you confirm that you are a qualified researcher and that this compound will be used exclusively for laboratory research purposes.
This product is not intended for diagnostic or therapeutic use.
Any human or medical use is strictly prohibited.
Store in a cool, dry, secure and sterile environment away from any unauthorised persons or children.
Disclaimer: All products are sold strictly for laboratory research purposes only. Not for human or veterinary use, consumption, therapeutic, or diagnostic application. By purchasing, you confirm you are a qualified professional and legally permitted to handle these materials in compliance with all applicable laws and regulations. Misuse, resale for unauthorised purposes, or unlawful application is strictly prohibited. Crown Peptides UK disclaims all liability for improper use, handling, or regulatory non-compliance.